Trusted by biotech and pharma R&D teams, including...
Flexible collaboration models
Target Validation
Bring us your hardest, previously “undruggable” target. We run it through our platform to assess druggability before any long-term commitment.
- Feasibility & structure screen
- Rapid go / no-go read
- Low-friction entry point
Co-Development Programs
Joint discovery programs spanning target discovery through chemical optimisation, with shared milestones and shared upside.
- Target Discovery to lead optimisation
- Joint IP & milestone structures
- Embedded project teams
Platform Access & Licensing
Access Orion, Polaris, or Ara directly to power your own internal RNA-targeted discovery efforts.
- Data & model licensing
- Screening-as-a-service
- Custom platform integration
Data Licensing
License our proprietary in-house data sets, ideal for training AI or ML models on targeting RNA, RNA small molecules, and more.
- Worlds largest data sets for RNA discovery
- 3M+ small molecule datapoints
- 200k+ RNA structures
The Serna Bio Discovery Platform
Orion
RNA structure atlas
The world's largest dataset of experimentally determined, functional RNA structures — 200,000+ druggable RNA structures spanning key cancer drivers and previously undruggable targets (e.g. c-MYC, STATs, NF-κB). 100x larger than public datasets.
Chemical Library
RNA-Target hit discovery
A proprietary chemistry library consisting of over 60k+ RNA-targeting small molecules that assist with hit discovery and provide rapid SAR confirmation with selective RNA scaffolds that improves target hit rates 20x.
Polaris
GenAI chemistry engine
A generative chemistry platform trained on proprietary data, designing selective small molecules that modulate RNA function — unconstrained by human medicinal-chemistry priors, and benchmarked ahead of methods such as NVIDIA MolMIM for RNA-targeted small molecules and demonstrated to improve potency 10x in a single DMT cycle. (See our paper)
Ara
In-cell screening platform
A "kinome panel for RNA" — an in-cell chemi-transcriptomics screening platform that confirms selective, functional activity of small molecules against RNA targets.